Amylyx Pharmaceuticals (AMLX) Institutional Ownership

During the previous two years, 130 institutional investors and hedge funds held shares of Amylyx Pharmaceuticals. The most heavily invested institutionals were Point72 Asset Management L.P. ($78.63M), Marshall Wace LLP ($42.71M), Pictet Asset Management SA ($42.07M), Stonepine Capital Management LLC ($36.80M), Rock Springs Capital Management LP ($33.32M), Adage Capital Partners GP L.L.C. ($31.13M), and Perceptive Advisors LLC ($27.51M).Learn more on AMLX's institutional investors.

95.84% of Amylyx Pharmaceuticals stock is owned by institutional investors. Learn more on AMLX's institutional investor holdings.

Of the 105 institutional investors that purchased Amylyx Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: AQR Capital Management LLC ($3.22M), abrdn plc ($2.05M), Almitas Capital LLC ($1.90M), Point72 Asset Management L.P. ($1.66M), Stonepine Capital Management LLC ($1.39M), Acadian Asset Management LLC ($1.21M), and Farallon Capital Management LLC ($1.15M).

Institutional investors have bought a total of 26,222,920 shares in the last 24 months. This purchase volume represents approximately $359.08M in transactions.

Of the 41 institutional investors that sold Amylyx Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Perceptive Advisors LLC ($1.98M), Avidity Partners Management LP ($1.69M), Federated Hermes Inc. ($1.43M), Millennium Management LLC ($976.28K), Allspring Global Investments Holdings LLC ($528.07K), Sectoral Asset Management Inc. ($361.11K), and American Century Companies Inc. ($359.76K).

Institutional investors have sold a total of 9,125,312 shares in the last 24 months. This volume of shares sold represents approximately $132.88M in transactions.